<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02608476</url>
  </required_header>
  <id_info>
    <org_study_id>CB-03-01/26</org_study_id>
    <nct_id>NCT02608476</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cassiopea SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cassiopea SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety and efficacy of CB-03-01&#xD;
      cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial&#xD;
      acne vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2015</start_date>
  <completion_date type="Actual">February 21, 2018</completion_date>
  <primary_completion_date type="Actual">February 21, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of subjects in each treatment group achieving &quot;success&quot; at Week 12, with &quot;success&quot; defined as an IGA score of &quot;clear (score=0)&quot; or &quot;almost clear (score=1)&quot; and at least a two-point reduction in IGA compared to Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Non-inflammatory Lesion (NIL) Counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Inflammatory Lesion (IL) Counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Lesion Counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Absolute change from Baseline in total lesions counts in each treatment group at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Lesion Counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percent change from Baseline in total lesions counts in each treatment group at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-inflammatory Lesion Counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Inflammatory Lesion Counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Local Site Reactions</measure>
    <time_frame>Baseline, Weeks 4, 8, and 12</time_frame>
    <description>Local Site Reactions (LSRs) including telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, stinging/burning, and pruritus scored by frequency and severity at every visit (Baseline, Weeks 4, 8, and 12).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">732</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>CB-03-01 cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-03-01 cream, 1% applied twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream applied twice daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-03-01 cream, 1%</intervention_name>
    <description>CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.</description>
    <arm_group_label>CB-03-01 cream</arm_group_label>
    <other_name>cortexolone 17α-propionate</other_name>
    <other_name>clascoterone (USAN, INN)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle cream</intervention_name>
    <description>Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.</description>
    <arm_group_label>Vehicle cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is male or non-pregnant female, 9 years of age or older. Females must be&#xD;
             post-menopausal, surgically sterile, or using highly effective birth control methods.&#xD;
             Women of child-bearing potential must have a negative urine pregnancy test (UPT) at&#xD;
             the Screening/Baseline Visit.&#xD;
&#xD;
          2. Subject has provided written and verbal informed consent/assent. A subject under 18&#xD;
             years of age must provide written informed assent and be accompanied by the parent or&#xD;
             legal guardian at the time of assent/consent signing.&#xD;
&#xD;
          3. Subject has an Investigator's Global Assessment (IGA) score of 3 (moderate) or 4&#xD;
             (severe) [0 (clear) to 4 (severe) scale].&#xD;
&#xD;
          4. Subject has facial acne vulgaris with at least 30 to a maximum of 75 inflammatory&#xD;
             lesions (papules, pustules, and nodules) and 30 to a maximum of 100 non-inflammatory&#xD;
             lesions (open and closed comedones).&#xD;
&#xD;
          5. Subject and parent/guardian (if applicable) are willing to comply with study&#xD;
             instructions and return to the clinic for required visits.&#xD;
&#xD;
          6. Subject has used the same type and brand of make-up, other facial products (exclusive&#xD;
             of RX/OTC acne cleansers) and hair products (e.g., shampoo, gel, hair spray, mousse,&#xD;
             etc.) for at least one (1) month prior to the Baseline Visit and agrees to continue&#xD;
             his/her other general skin and hair care products and regimen for the entire study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is pregnant, lactating, or is planning to become pregnant during the study.&#xD;
&#xD;
          2. Subject has any skin pathology or condition that could interfere with the evaluation&#xD;
             of the test products or requires the use of interfering topical or systemic therapy.&#xD;
&#xD;
          3. Subject has greater than two (2) facial nodules.&#xD;
&#xD;
          4. Subject has nodulocystic acne.&#xD;
&#xD;
          5. Subject has any condition which, in the investigator's opinion, would make it unsafe&#xD;
             for the subject to participate in this research study.&#xD;
&#xD;
          6. Subject is currently enrolled in an investigational drug or device study.&#xD;
&#xD;
          7. Subject has received an investigational drug or has been treated with an&#xD;
             investigational device within 30 days prior to the initiation of treatment (Baseline).&#xD;
&#xD;
          8. Subject has facial hair that could interfere with the study assessments in the opinion&#xD;
             of the investigator.&#xD;
&#xD;
          9. Subject and parent/guardian (if applicable) are unable to communicate or cooperate&#xD;
             with the investigator due to language problems, poor mental development, or impaired&#xD;
             cerebral function.&#xD;
&#xD;
         10. Subject may be unreliable for the study including subjects who engage in excessive&#xD;
             alcohol intake or drug abuse, or subjects who are unable to return for scheduled&#xD;
             follow-up visits.&#xD;
&#xD;
         11. Subject has known hypersensitivity or previous allergic reaction to any of the active&#xD;
             or inactive components of the test articles.&#xD;
&#xD;
         12. Subject has the need or plans to be exposed to artificial tanning devices or excessive&#xD;
             sunlight during the trial.&#xD;
&#xD;
         13. Subject has used any of the prohibited topical anti-acne treatments or procedures&#xD;
             prior to the study unless appropriate washout period is documented.&#xD;
&#xD;
         14. Subject has used used any of the prohibited systemic anti-acne medications prior to&#xD;
             the study unless appropriate washout period is documented.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R&amp;D Cassiopea</last_name>
    <role>Study Director</role>
    <affiliation>Cassiopea S.p.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clear dermatology &amp; Aesthetic Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson Dermatology</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology and Laser Surgery</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belleair Research Center</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Dermatology</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Dermatology, PA</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Laser Skin and Vein Institute</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadick Research Group, LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialty Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3521</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3523</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3525</name>
      <address>
        <city>Sofia</city>
        <zip>1404</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3520</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3524</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3519</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3526</name>
      <address>
        <city>Sofia</city>
        <zip>1618</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3522</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9923</name>
      <address>
        <city>Batumi</city>
        <zip>6010</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9924</name>
      <address>
        <city>Kutaisi</city>
        <zip>4600</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9921</name>
      <address>
        <city>Tbilisi</city>
        <zip>0145</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9920</name>
      <address>
        <city>Tbilisi</city>
        <zip>0177</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9922</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9925</name>
      <address>
        <city>Zugdidi</city>
        <zip>2100</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4819</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-863</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4814</name>
      <address>
        <city>Czestochowa</city>
        <zip>15-794</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4822</name>
      <address>
        <city>Czestochowa</city>
        <zip>42-217</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4815</name>
      <address>
        <city>Katowice</city>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4811</name>
      <address>
        <city>Katowice</city>
        <zip>62-069</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4821</name>
      <address>
        <city>Kraków</city>
        <zip>30-002</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4815</name>
      <address>
        <city>Kraków</city>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4813</name>
      <address>
        <city>Kraków</city>
        <zip>70-332</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4823</name>
      <address>
        <city>Osielsko</city>
        <zip>86-031</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4816</name>
      <address>
        <city>Rzeszów</city>
        <zip>61-113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4812</name>
      <address>
        <city>Szczecin</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4818</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4820</name>
      <address>
        <city>Łódź</city>
        <zip>91-334</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4033</name>
      <address>
        <city>Sector 2</city>
        <state>Bucharest</state>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4034</name>
      <address>
        <city>Sector 2</city>
        <state>Bucharest</state>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4031</name>
      <address>
        <city>Sector 3</city>
        <state>Bucharest</state>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4029</name>
      <address>
        <city>Sector 6</city>
        <state>Bucharest</state>
        <zip>062272</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4028</name>
      <address>
        <city>Târgovişte</city>
        <state>Jud. Dambovita</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4036</name>
      <address>
        <city>Bucarest</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4035</name>
      <address>
        <city>Bucharest</city>
        <zip>011025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4032</name>
      <address>
        <city>Craiova</city>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4037</name>
      <address>
        <city>Iaşi</city>
        <zip>700381</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4030</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 8138</name>
      <address>
        <city>Belgrade</city>
        <zip>11050</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 8137</name>
      <address>
        <city>Belgrade</city>
        <zip>8137</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 8136</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://usacnestudy.com/</url>
    <description>Study Website</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <results_first_submitted>September 23, 2020</results_first_submitted>
  <results_first_submitted_qc>October 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2020</results_first_posted>
  <disposition_first_submitted>June 10, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>June 10, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 12, 2019</disposition_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne</keyword>
  <keyword>clascoterone</keyword>
  <keyword>anti-androgen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 11, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02608476/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02608476/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CB-03-01 Cream</title>
          <description>CB-03-01 cream, 1% applied twice daily for 12 weeks&#xD;
Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a&#xD;
1% cream for the topical treatment of acne vulgaris.</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Cream</title>
          <description>Vehicle cream applied twice daily for 12 weeks&#xD;
Vehicle cream: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="369"/>
                <participants group_id="P2" count="363"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="302"/>
                <participants group_id="P2" count="282"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Parent/Guardian</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat population; defined as all subjects randomized and whom received at least one dose of study medication, including vehicle.</population>
      <group_list>
        <group group_id="B1">
          <title>CB-03-01 Cream</title>
          <description>CB-03-01 cream, 1% applied twice daily for 12 weeks&#xD;
Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a&#xD;
1% cream for the topical treatment of acne vulgaris.</description>
        </group>
        <group group_id="B2">
          <title>Vehicle Cream</title>
          <description>Vehicle cream applied twice daily for 12 weeks&#xD;
Vehicle cream: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="369"/>
            <count group_id="B2" value="363"/>
            <count group_id="B3" value="732"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.3" spread="5.6"/>
                    <measurement group_id="B2" value="19.0" spread="5.4"/>
                    <measurement group_id="B3" value="19.2" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="464"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                    <measurement group_id="B2" value="354"/>
                    <measurement group_id="B3" value="703"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="357"/>
                    <measurement group_id="B2" value="348"/>
                    <measurement group_id="B3" value="705"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline IGA</title>
          <description>Investigator's Global Assessment (IGA)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 - Clear</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 - Almost Clear</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 - Mild</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 - Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="305"/>
                    <measurement group_id="B2" value="313"/>
                    <measurement group_id="B3" value="618"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 - Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Acne Lesion Counts</title>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Non-inflammatory lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="21.4"/>
                    <measurement group_id="B2" value="63.3" spread="20.5"/>
                    <measurement group_id="B3" value="63.1" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammatory lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" spread="12.2"/>
                    <measurement group_id="B2" value="41.3" spread="11.0"/>
                    <measurement group_id="B3" value="42.1" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105.7" spread="25.8"/>
                    <measurement group_id="B2" value="104.6" spread="24.2"/>
                    <measurement group_id="B3" value="105.2" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)</title>
        <description>Percentage of subjects in each treatment group achieving &quot;success&quot; at Week 12, with &quot;success&quot; defined as an IGA score of &quot;clear (score=0)&quot; or &quot;almost clear (score=1)&quot; and at least a two-point reduction in IGA compared to Baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>Intent-to-treat (ITT) population, which included all randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>CB-03-01 Cream</title>
            <description>CB-03-01 cream, 1% applied twice daily for 12 weeks&#xD;
Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a&#xD;
1% cream for the topical treatment of acne vulgaris.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream</title>
            <description>Vehicle cream applied twice daily for 12 weeks&#xD;
Vehicle cream: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)</title>
          <description>Percentage of subjects in each treatment group achieving &quot;success&quot; at Week 12, with &quot;success&quot; defined as an IGA score of &quot;clear (score=0)&quot; or &quot;almost clear (score=1)&quot; and at least a two-point reduction in IGA compared to Baseline.</description>
          <population>Intent-to-treat (ITT) population, which included all randomized subjects</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Non-inflammatory Lesion (NIL) Counts</title>
        <description>Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>CB-03-01 Cream</title>
            <description>CB-03-01 cream, 1% applied twice daily for 12 weeks&#xD;
Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a&#xD;
1% cream for the topical treatment of acne vulgaris.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream</title>
            <description>Vehicle cream applied twice daily for 12 weeks&#xD;
Vehicle cream: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Non-inflammatory Lesion (NIL) Counts</title>
          <description>Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.</description>
          <population>ITT population.</population>
          <units>Non-inflammatory lesions</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.4" lower_limit="-22.1" upper_limit="-16.7"/>
                    <measurement group_id="O2" value="-10.8" lower_limit="-13.6" upper_limit="-8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Inflammatory Lesion (IL) Counts</title>
        <description>Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>CB-03-01 Cream</title>
            <description>CB-03-01 cream, 1% applied twice daily for 12 weeks&#xD;
Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a&#xD;
1% cream for the topical treatment of acne vulgaris.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream</title>
            <description>Vehicle cream applied twice daily for 12 weeks&#xD;
Vehicle cream: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inflammatory Lesion (IL) Counts</title>
          <description>Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.</description>
          <population>ITT population.</population>
          <units>Inflammatory lesions</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.0" lower_limit="-21.7" upper_limit="-18.3"/>
                    <measurement group_id="O2" value="-12.6" lower_limit="-14.3" upper_limit="-10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Lesion Counts</title>
        <description>Absolute change from Baseline in total lesions counts in each treatment group at Week 12.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>CB-03-01 Cream</title>
            <description>CB-03-01 cream, 1% applied twice daily for 12 weeks&#xD;
Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a&#xD;
1% cream for the topical treatment of acne vulgaris.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream</title>
            <description>Vehicle cream applied twice daily for 12 weeks&#xD;
Vehicle cream: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Lesion Counts</title>
          <description>Absolute change from Baseline in total lesions counts in each treatment group at Week 12.</description>
          <population>ITT population.</population>
          <units>total lesions</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.0" lower_limit="-43.8" upper_limit="-36.2"/>
                    <measurement group_id="O2" value="-23.6" lower_limit="-27.8" upper_limit="-19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Lesion Counts</title>
        <description>Percent change from Baseline in total lesions counts in each treatment group at Week 12.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>CB-03-01 Cream</title>
            <description>CB-03-01 cream, 1% applied twice daily for 12 weeks&#xD;
Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a&#xD;
1% cream for the topical treatment of acne vulgaris.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream</title>
            <description>Vehicle cream applied twice daily for 12 weeks&#xD;
Vehicle cream: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Lesion Counts</title>
          <description>Percent change from Baseline in total lesions counts in each treatment group at Week 12.</description>
          <population>ITT population.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.3" lower_limit="-41.1" upper_limit="-33.6"/>
                    <measurement group_id="O2" value="-22.1" lower_limit="-26.1" upper_limit="-18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-inflammatory Lesion Counts</title>
        <description>Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>CB-03-01 Cream</title>
            <description>CB-03-01 cream, 1% applied twice daily for 12 weeks&#xD;
Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a&#xD;
1% cream for the topical treatment of acne vulgaris.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream</title>
            <description>Vehicle cream applied twice daily for 12 weeks&#xD;
Vehicle cream: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-inflammatory Lesion Counts</title>
          <description>Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.</description>
          <population>ITT population.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.3" lower_limit="-33.7" upper_limit="-24.9"/>
                    <measurement group_id="O2" value="-15.6" lower_limit="-20.3" upper_limit="-10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Inflammatory Lesion Counts</title>
        <description>Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>CB-03-01 Cream</title>
            <description>CB-03-01 cream, 1% applied twice daily for 12 weeks&#xD;
Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a&#xD;
1% cream for the topical treatment of acne vulgaris.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream</title>
            <description>Vehicle cream applied twice daily for 12 weeks&#xD;
Vehicle cream: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Inflammatory Lesion Counts</title>
          <description>Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.</description>
          <population>ITT population.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.9" lower_limit="-50.9" upper_limit="-42.8"/>
                    <measurement group_id="O2" value="-29.6" lower_limit="-33.9" upper_limit="-25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Local Site Reactions</title>
        <description>Local Site Reactions (LSRs) including telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, stinging/burning, and pruritus scored by frequency and severity at every visit (Baseline, Weeks 4, 8, and 12).</description>
        <time_frame>Baseline, Weeks 4, 8, and 12</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) and serious adverse events (SAEs) were collected from screening visit, Baseline (Day 1) and up to Week 12/early termination.</time_frame>
      <desc>The Safety population was used for all analyses which comprised of all participants enrolled in the study and applied at least on dose of the test article.</desc>
      <group_list>
        <group group_id="E1">
          <title>CB-03-01 Cream</title>
          <description>CB-03-01 cream, 1% applied twice daily for 12 weeks&#xD;
Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a&#xD;
1% cream for the topical treatment of acne vulgaris.</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Cream</title>
          <description>Vehicle cream applied twice daily for 12 weeks&#xD;
Vehicle cream: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.8</frequency_threshold>
        <default_vocab>MedDRA version 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 18 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 60 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cassiopea R&amp;D</name_or_title>
      <organization>Cassiopea, SPA</organization>
      <phone>+39 02 868 911 24</phone>
      <email>r&amp;d@cassiopea.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

